Clinigen Group Revenue and Competitors

Burton on Trent, UK

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Clinigen Group's estimated annual revenue is currently $142.7M per year.(i)
  • Clinigen Group's estimated revenue per employee is $201,000

Employee Data

  • Clinigen Group has 710 Employees.(i)
  • Clinigen Group grew their employee count by 10% last year.

Clinigen Group's People

NameTitleEmail/Phone
1
General Counsel and Company SecretaryReveal Email/Phone
2
Commercial Director (Licensed) Immunology and OncologyReveal Email/Phone
3
Senior Director, ProductsReveal Email/Phone
4
IMP Production OfficerReveal Email/Phone
5
Director Warehouse OperationsReveal Email/Phone
6
Program Manager - Managed AccessReveal Email/Phone
7
Pharmacovigilance Quality & Compliance ManagerReveal Email/Phone
8
Customer Services Training ManagerReveal Email/Phone
9
Strategic Account ManagerReveal Email/Phone
10
Senior Medical Science LiaisonReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$58.9M2936%N/AN/A
#2
$21.1M1055%N/AN/A
#3
$113.4M5641%N/AN/A
#4
$20.9M104-5%N/AN/A
#5
$37M1849%N/AN/A
#6
$45.4M226-24%N/AN/A
#7
$16.1MN/AN/AN/A
#8
$69.7M3470%N/AN/A
#9
$8M403%N/AN/A
#10
$25.5M12728%N/AN/A
Add Company

What Is Clinigen Group?

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinical Trial Services Clinigen is the global market leader in the specialist supply and management of quality-assured comparator medicines and services to clinical trials and Investigator Initiated Trials. Unlicensed Medicines Clinigen is the global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Group manages early access programmes to innovative new medicines and provides on demand access globally to medicines which remain unlicensed at the point of care. Commercial Medicines Clinigen acquires global rights to niche hospital only and critical care products, revitalising these assets around the world and returning them back to sustained growth. It also provides access to licensed and branded generic medicines in the Africa and Asia Pacific region. The Group also has an unlicensed to licensed strategy, where it looks to take unlicensed medicines with commercial potential and licence them, helping to address unmet medical need and allowing the Group to capitalise on its market-leading positions. Clinigen supplies to more than 130 countries across the world from its global offices in the United Kingdom, United States, Japan, Singapore, Australia, New Zealand and South Africa.

keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals

N/A

Total Funding

710

Number of Employees

$142.7M

Revenue (est)

10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Clinigen Group News

2022-04-20 - Amifostine Market Size, Outlook And Forecast | Clinigen ...

Clinigen Group, Sun Pharmaceutical, Taj Pharmaceuticals, Merro Pharmaceutical, Luye Pharma, Mingren Pharma. This comprehensive Amifostine Market report...

2022-03-30 - HSBC Bank Plc - Form 8.5 (EPT/RI) - Clinigen Group PLC

HSBC Bank Plc - Form 8.5 (EPT/RI) - Clinigen Group PLC · 1. KEY INFORMATION. (a) Name of exempt principal trader: · 2. DEALINGS BY THE EXEMPT...

2022-03-22 - Form 8.3 - Clinigen Group plc

Form 8.3 - Clinigen Group plc · 1. KEY INFORMATION. (a) Identity of the person whose positions/dealings are being disclosed: · 2. POSITIONS OF THE...

2021-09-02 - PAION : SIGNS EXCLUSIVE UK SUPPLY AND DISTRIBUTION AGREEMENT WITH CLINIGEN

DGAP-News: PAION AG / Key word(s): Miscellaneous PAION SIGNS EXCLUSIVE UK SUPPLY AND DISTRIBUTION AGREEMENT WITH CLINIGEN 02.09.2021 / 14:00 The issuer is solely responsible for the content of this announcement. PAION SIGNS EXCLUSIVE UK SUPPLY AND DISTRIBUTION AGREEMENT WITH CLINIGEN Aachen ...

2021-04-08 - CLINIGEN GROUP PLC Clinigen : launches Managed Access Program with BeiGene for zanubrutinib

medicineaccess@clinigengroup.com. 8 April 2021 Clinigen launches Managed Access Program with BeiGene for zanubrutinib Clinigen Group plc (AIM: CLIN, 'Clinigen'), the global pharmaceutical Products and Services company, has launched a Managed Access Program (MAP) for BeiGene, Ltd. , a commerci ...